

Almirall participates in Global Health Summit to raise awareness of the mental health burden of skin diseases

LONDON, UNITED KINGDOM, May 31, 2024 /EINPresswire.com/ -- Almirall is committed to raising awareness about the mental health burden associated with chronic skin diseases, which can lead to anxiety, depression, and social isolation.

“

The mental load is a massive part of the condition, there's all of these layers, and I think it's so important we keep talking about all facets of this condition that affect people differently,”

declared Linzi Dunlevy, IFPA ambassador and living with psoriasis

The company is at the forefront of research that examines both the physical and psychological impact of skin diseases, conducting first-of-a-kind clinical studies like POSITIVE, PROSES, and PROAK

The documentary “Skin- beyond the surface”, presented by Almirall at the Global Health Summit, focuses on the experiences and challenges faced by patients with dermatological conditions such as psoriasis and atopic dermatitis

Almirall, a global pharmaceutical company dedicated to medical dermatology is participating in the Global Health Summit, coinciding with the 77th World Health Assembly

(WHA) in Geneva, to raise awareness of the mental health burden of skin diseases. This gathering of healthcare specialists addresses some of the most pressing global health challenges.

The severity of skin conditions is often underestimated because they are frequently classified as non-life threatening. However, these diseases often have a significant impact on the lives of patients and their families. Almirall is committed to raising awareness about the mental health burden associated with chronic skin diseases, which can lead to anxiety, depression, and social isolation. The pharmaceutical company goes beyond addressing the physical burden of skin diseases taking into account the non-physical symptoms that can significantly affect patients' lives. "We strive to understand our patients and find real and impactful solutions for them," said Volker Koscielny, Almirall's Chief Medical Officer. "Our leadership is firmly rooted in recognizing that medical dermatology is much more than physical outcomes, and understanding the mental impact of skin diseases is absolutely crucial. We ask ourselves: can we give patients with skin

diseases their lives back through effective treatments?"

Almirall's promise to patients and healthcare professionals is to develop innovative solutions that allow them to lead a normal life and overcome daily obstacles. Mercedes Diz, Almirall's Chief Marketing Officer, highlighted: "Our job is to bring effective medicines to patients to allow them to live as fulfilled a life as they possibly can. That's why we put so much effort into finding innovative medicines designed to address skin conditions that can really make a difference to people, including their emotional wellbeing and social life."

Leading the field in addressing the wellbeing of people with skin diseases

Almirall is at the forefront of research that evaluates both physical and psychological impact of skin diseases. The POSITIVE study, initiated in 2021, is the first clinical study in dermatology to assess patients' wellbeing as a primary endpoint, using the WHO-5 well-being index. This study aims to determine whether treatments like the biologic tildrakizumab can significantly improve patients' psychological and social health alongside skin clearance.

Additionally, Almirall's PROSES study for sarecycline evaluates the impact of acne treatment on health-related quality of life (HRQOL) outcomes, including anxiety, social activities, and self-perception. The PROAK study assesses patient-reported outcomes for those suffering from Actinic Keratosis, a common condition that could evolve to squamous cell carcinoma (SCC). This multi-centre trial used an innovative new health-related patient-reported outcome questionnaire, the AK-EPQ, to capture the disease-specific perspectives not fully reflected in existing questionnaires.

Launching the Almirall documentary "Skin- beyond the surface"

Almirall commitment to raising awareness on skin diseases and innovative work in dermatology is featured in a documentary distributed through Reuters as part of the Global Health Summit activities.

The video focuses on the experiences and challenges faced by patients with dermatological conditions such as psoriasis and atopic dermatitis. It highlights the severe impact these conditions have on patients' mental health, self-esteem, and daily life. The documentary also features perspectives from healthcare professionals and industry leaders at Almirall. The experts emphasize the importance of addressing both the physical and emotional aspects of these conditions, and the company's commitment to developing treatments that improve overall wellbeing.

"The mental load is a massive part of the condition, there's all of these layers, and I think it's so important we keep talking about all facets of this condition that affect people differently," declared Linzi Dunlevy, IFPA ambassador and living with psoriasis.

"Wellbeing in medicine is so fundamental because this is the primary goal we should have in

treatment. As physicians, as nurses and other healthcare professionals, we have the function to increase the level of health of everybody who comes to us. And health means, by definition of WHO, not the mere absence of disease, but a status of complete physical, emotional and social wellbeing", stated in the documentary Prof. Dr. Matthias Augustin, MD, PhD, Professor of Dermatology and Chair of Health Economics, University Medical Center of Hamburg

[Watch The Global Health Campaign Here](#)

About Almirall

Almirall is a global pharmaceutical company dedicated to medical dermatology. We closely collaborate with leading scientists, healthcare professionals, and patients to deliver our purpose: to transform the patients' world by helping them realize their hopes and dreams for a healthy life. We are at the forefront of science to deliver ground-breaking, differentiated medical dermatology innovations that address patients' needs.

Almirall, founded in 1944 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM). Almirall (total revenue in 2023: €898.8 MM, 1900 employees globally) has direct presence in 21 countries and marketed products in over 100.

For more information, please visit almirall.com

Corporate Communications:

corporate.communication@almirall.com

Phone: (+34) 659 614 173

Investor Relations

investors@almirall.com

Phone: (+34) 93 291 30 87

Lemia El Basri

Acumen Media

+44 20 3553 3664

[email us here](#)

Visit us on social media:

[X](#)

[LinkedIn](#)

[YouTube](#)

[Other](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/716141797>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire,

Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.